908 Devices Sees Strong Q4 Performance Amid Strategic Pivot to Frontline Chemical Detection.

908 Devices Inc reported strong Q4 performance driven by US state and local markets, international adoption of VipIR, and federal and defense customer sales. The company is strategically pivoting towards frontline chemical detection, with favorable macroeconomic trends such as increased funding for the opioid crisis and global defense budgets expected to bolster future growth. Revenue growth and positive Adjusted EBITDA were achieved, positioning the firm for future success.